MBX Biosciences, Inc..
MBX.US | Manufacture of pharmaceuticals, medicinal chemical and botanical products
MBX Biosciences, Inc. is a biopharmaceutical company focused on developing peptide therapeutics to treat endocrine disorders. Their primary focus is on developing therapies for hypoparathyroidism and other related conditions. The company utilizes its peptide platform to create novel treatments aimed...Show More
Better Health for All
-30
MBX Biosciences is a clinical-stage biopharmaceutical company entirely devoted to developing therapies for endocrine and metabolic disorders, including hypoparathyroidism, post-bariatric hypoglycemia, and obesity, which addresses significant unmet medical needs.
1
This aligns with 95-97% of its product portfolio delivering exceptional health benefits. As a biopharmaceutical company, 100% of its R&D budget is allocated to health improvement, utilizing its proprietary PEP platform technology to develop therapeutic candidates.
2
In Phase 1 clinical trials, canvuparatide was generally well-tolerated with no drug-related severe or serious adverse effects, indicating few safety incidents.
3
The company targets conditions like hypoparathyroidism, affecting over 260,000 people in the US, Europe, and Japan, and obesity, affecting 42.5% of US adults, but there is no evidence of specific programs to reach vulnerable populations, suggesting 45-55% of vulnerable populations are reached.
4
The company states that preclinical and early-stage clinical trial results may not be predictive of later-stage trials, and positive results may not be replicated, indicating that most major risks are disclosed but claims are only partially substantiated.
5
MBX addresses the bias and stigma faced by individuals with obesity, which represents a moderate health equity program.
6
The company aims to prevent severe hypoglycemia in individuals with post-bariatric hypoglycemia, indicating a growing prevention focus.
7
Phase 1 trials focus on safety, tolerability, and pharmacokinetics, while Phase 2 trials assess efficacy and safety in a broader patient population, suggesting improving ethical standards in trials.
8
Fair Money & Economic Opportunity
0
MBX Biosciences, Inc. is a biopharmaceutical company focused on developing peptide therapeutics.
1
Its core business does not involve lending, insuring, moving, or storing money for consumers, nor does it offer financial services or products.
2
Therefore, all KPIs related to fair money and economic opportunity, which are designed for financial institutions, are not applicable to its operations.
Fair Pay & Worker Respect
0
No verifiable, company-specific data was found in the provided articles to assess MBX.US against the 'Fair Pay & Worker Respect' value. While one article provided estimated salary data and cost of living information, it explicitly stated that this data was derived from a proprietary algorithm and not based on company records or surveys, rendering it unsuitable as evidence for scoring.
1
No other articles contained relevant quantitative data for any of the specified KPIs.
Fair Trade & Ethical Sourcing
0
The provided articles, which include financial reports, corporate governance guidelines, and a code of business conduct and ethics, do not contain any specific information or data points related to fair trade and ethical sourcing within the company's supply chain. There is no evidence regarding fair-trade certifications, supplier audit frequency, forced or child labor incidents, traceability coverage, remediation speed for violations, ethical clauses in supplier contracts, share of spend on high-risk materials, or supplier diversity spend.
1
Honest & Fair Business
-10
MBX Biosciences, Inc. adopted a Code of Business Conduct and Ethics on August 26, 2024, which includes whistleblower protection provisions.
1
The company forbids retaliation against employees who report suspected misconduct in good faith and provides an internal ethics hotline and an online reporting option, allowing for anonymous reporting.
2
However, there is no public information on the effectiveness of the program or uptake rates. As of April 7, 2025, eight out of nine board members are independent, representing approximately 89% of the board.
3
The company's Code of Business Conduct and Ethics also includes a Foreign Corrupt Practices Act and Anti-Corruption Policy, which prohibits bribes, kickbacks, and other improper payments, but there is no evidence of specific training frequency, risk assessments, or third-party monitoring.
4
Kind to Animals
-20
MBX Biosciences conducts pre-clinical studies on animals to assess the safety profile of its drugs.
1
The company has stated that a significant delay in accessing animal research models would materially and adversely affect its ability to advance preclinical programs and successfully develop product candidates.
2
No War, No Weapons
0
No evidence available to assess MBX Biosciences, Inc. on No War, No Weapons.
Planet-Friendly Business
0
No evidence available to assess MBX Biosciences, Inc. on Planet-Friendly Business.
Respect for Cultures & Communities
0
No specific, concrete data points were found in the provided articles regarding MBX.US's performance on any of the KPIs related to Respect for Cultures & Communities. The articles focus on general topics such as global health initiatives, research ethics, and clinical trial guidelines, without mentioning MBX.US or its specific actions, policies, or engagement with local communities or cultural aspects.
Safe & Smart Tech
0
No specific, concrete data points were found in the provided articles for any of the Safe & Smart Tech KPIs.
1
The articles primarily consist of corporate governance overviews and terms of use, and explicitly state the absence of information relevant to these metrics.
2
The SEC filing was inaccessible, providing no additional data.
3
Zero Waste & Sustainable Products
0
No data related to waste diversion rates, product recyclability, packaging sustainability, recycled content, single-use plastic reduction, take-back programs, circular design, waste reduction initiatives, hazardous waste management, product durability, repairability, waste audit frequency, zero waste certification, waste disposal violations, material efficiency, packaging-to-product ratio, waste reduction targets, supplier waste requirements, or customer waste education is presented in the provided articles.
1
The articles focus on the company's therapeutics pipeline or are unrelated.
2